HKSE - Delayed Quote ? HKD Innovent Biologics, Inc. (1801.HK) Follow Compare 45.350 -0.350 (-0.77%) As of 11:59 AM GMT+8. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Innovent’s trial of picankibart for ulcerative colitis meets primary endpoint The primary endpoint was clinical remission at week 12, with secondary endpoints of clinical response and endoscopic remission. Clinical Trials Arena ? 5 days ago IVBIY Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis Met Primary Endpoint Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that primary endpoint of 12-week induction period was met in a multicenter, randomized, double-blind, placebo-controlled phase 2 clinical study (ClinicalTrials.gov, NCT05377580) of picankibart (R&D code: IBI112), a PR Newswire ? 6 days ago IVBIY IVBXF High Growth Tech Stocks In Hong Kong October 2024 As geopolitical tensions and economic uncertainties weigh on global markets, the Hong Kong tech sector has shown resilience, with the Hang Seng Index climbing 10.2% amid optimism about China's supportive measures. In this environment, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation capabilities and adaptability to shifting market dynamics, which are crucial in navigating the current landscape. Simply Wall St. ? 11 days ago FITGF IVBIY IVBXF High Growth Tech Stocks in Hong Kong for October 2024 As global markets navigate geopolitical tensions and economic shifts, Hong Kong's tech sector has shown resilience, with the Hang Seng Index climbing 10.2% amid optimism surrounding Beijing's supportive measures. In this dynamic environment, identifying high-growth tech stocks requires careful consideration of innovation potential and adaptability to market changes, making them attractive prospects for those looking to capitalize on technological advancements in a rapidly evolving landscape. Simply Wall St. ? 12 days ago IVBIY IVBXF FITGF Top High Growth Tech Stocks In Hong Kong October 2024 In October 2024, the Hong Kong market has been experiencing a significant upswing, with the Hang Seng Index climbing 10.2% amid optimism surrounding Beijing's supportive measures despite broader global tensions and economic uncertainties. In this dynamic environment, identifying high-growth tech stocks involves looking for companies that not only demonstrate strong innovation and adaptability but also have the potential to capitalize on favorable policy shifts and market trends. Simply Wall St. ? 12 days ago 6990.HK FITGF IVBIY High Growth Tech Stocks In Hong Kong This October 2024 As geopolitical tensions in the Middle East have led to volatile oil prices and mixed sentiment across global markets, Hong Kong's tech sector has shown resilience with the Hang Seng Index climbing 10.2% amid optimism over Beijing's support measures. In such a dynamic environment, identifying high-growth tech stocks involves looking for companies that are well-positioned to leverage technological advancements and adapt to shifting economic conditions while maintaining robust financial health. Simply Wall St. ? 13 days ago 6990.HK FITGF IVBIY Exploring 3 High Growth Tech Stocks in Hong Kong In recent weeks, the Hong Kong market has experienced a notable surge, with the Hang Seng Index climbing 10.2% amid optimism surrounding Beijing's supportive measures despite some disappointing economic data. As investors navigate these dynamic conditions, identifying high-growth tech stocks becomes crucial; such stocks typically demonstrate strong potential for innovation and adaptability in response to evolving market trends and economic shifts. Simply Wall St. ? 14 days ago 6990.HK FITGF IVBIY Innovent and ASK Pharm to commercialise limertinib for lung cancer ASK Pharm is entitled to receive upfront payments and milestone payments. Pharmaceutical Technology ? 14 days ago IVBIY Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, and Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm, 002755.SZ), announced that the two parties have entered into a strategic collaboration regarding limertinib, a third-generation epidermal growth factor receptor (EG PR Newswire ? 15 days ago IVBIY IVBXF 3 SEHK Stocks That May Be Undervalued By Up To 48.6% In recent months, the Hong Kong market has shown resilience despite global economic uncertainties, with the Hang Seng Index gaining over 5% in a holiday-shortened week. Investors are closely watching how rate cuts by major central banks might influence market sentiment and economic growth. Identifying undervalued stocks in such an environment requires a keen eye for companies with strong fundamentals that may not yet be fully appreciated by the market. Here are three SEHK stocks that could... Simply Wall St. ? 26 days ago 2268.HK ZHAOF IVBIY Innovent Announces NMPA Acceptance of NDA for Picankibart (Anti-IL-23p19 Antibody) for Treating Moderate to Severe Plaque Psoriasis Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the New Drug Application (NDA) for picankibart injection, a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody, has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical PR Newswire ? 27 days ago IVBIY IVBXF Innovent Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that clinical data of IBI363 (first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein) combined with bevacizumab in advanced colorectal cancer is presented at the 2024 ESMO Congress. Currently, Innovent i PR Newswire ? last month IVBIY IVBXF Innovent Delivers Oral Presentations on Clinical Data of IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate) in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors at the 2024 ESMO Congress Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announced that clinical data of IBI354 (HER2 monoclonal antibody-camptothecin derivative conjugate) in advanced solid tumors was presented at the 2024 ESMO Congress (ClinicalTrials.gov, NCT05636215). PR Newswire ? last month IVBIY IVBXF EASD 2024: Innovent shows off mazdutide’s efficacy in diabetes and obesity The data from two Phase III trials demonstrated GLP-1/glucagon agonist’s efficacy in reducing blood glucose and weight. Pharmaceutical Technology ? last month IVBIY LLY High Growth Tech Stocks in Hong Kong to Watch This September 2024 As global markets face heightened volatility and economic uncertainties, the Hong Kong market has not been immune to these pressures, with the Hang Seng Index recently experiencing a notable decline. Despite this backdrop, investors continue to seek opportunities in high-growth sectors such as technology, which remains a focal point for potential long-term gains. In this environment, identifying stocks with strong fundamentals and innovative capabilities becomes crucial for navigating market... Simply Wall St. ? last month AKESF IVBIY IVBXF Head-to-head Superiority over Dulaglutide: Innovent's Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes were Orally Presented at EASD 2024 Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the Phase 3 clinical trial results for mazdutide, a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese adults with type 2 diabetes (T2D) (DREAMS-2) were presented as PR Newswire ? last month IVBIY IVBXF High Growth Tech Stocks To Watch In Hong Kong This September 2024 As global markets face a downturn, with the S&P 500 experiencing its worst weekly drop in 18 months and Hong Kong's Hang Seng Index also retreating, investors are increasingly cautious about economic slowdowns and market volatility. In this climate, identifying high-growth tech stocks in Hong Kong requires a keen eye for companies with strong fundamentals, innovative capabilities, and resilience to broader market pressures. Simply Wall St. ? last month 6990.HK AKESF IVBIY Innovent Delivers Oral Presentation on Phase 1 Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer at the 2024 WCLC Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announced the presentation of Phase 1 clinical data (ClinicalTrials.gov, NCT04085185) for IBI363 (first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein) in advanced non-small cell lung cancer at the 2024 World Co PR Newswire ? last month IVBIY IVBXF Innovent Delivers Oral Presentation of Updated Results from a Pivotal Phase 2 Study of Dupert? (Fulzerasib) in Patients with Advanced Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces an oral presentation of updated results from a pivotal Phase 2 clinical trial of Dupert?（fulzerasib）for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutat PR Newswire ? last month IVBIY IVBXF High Growth Tech Stocks to Watch in Hong Kong September 2024 As global markets face economic uncertainties, the Hang Seng Index in Hong Kong has mirrored broader sentiments with notable fluctuations. Despite these challenges, identifying high-growth tech stocks remains crucial for investors seeking opportunities in a volatile market environment. Simply Wall St. ? last month 6990.HK VOBIF IVBIY Performance Overview Trailing total returns as of 10/23/2024, which may include dividends or other distributions. Benchmark is HANG SENG INDEX Return 1801.HK HANG SENG INDEX YTD +6.08% +22.26% 1-Year +2.83% +21.37% 3-Year -40.83% -20.23%
